CRINETICS PHARMACEUTICALS INC. - COMMON STOCK
40.59
10-January-25 16:45:00
15 minutes delayed
Stocks
-7.91
-16.31%
Today's range
40.04 - 47.56
ISIN
N/A
Source
NASDAQ
-
Crinetics to Highlight Broad Pipeline at ENDO 2023
09 Jun 2023 07:30:08 By Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 May 2023 16:21:55 By Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
04 May 2023 16:05:12 By Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Apr 2023 16:31:01 By Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Mar 2023 16:37:50 By Nasdaq GlobeNewswire
-
28 Feb 2023 16:05:39 By Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Feb 2023 17:21:42 By Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
10 Feb 2023 08:01:33 By Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Jan 2023 16:48:48 By Nasdaq GlobeNewswire
-
09 Jan 2023 08:01:39 By Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 Dec 2022 16:01:00 By Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Provides Update on CRN04777 Program
28 Nov 2022 08:00:01 By Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
22 Nov 2022 08:00:02 By Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
14 Nov 2022 08:00:02 By Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Nov 2022 16:30:43 By Nasdaq GlobeNewswire
-
13 Oct 2022 08:00:02 By Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Oct 2022 16:57:25 By Nasdaq GlobeNewswire
-
Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism
06 Oct 2022 08:00:02 By Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer
03 Oct 2022 08:00:01 By Nasdaq GlobeNewswire
-
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 Sep 2022 08:00:01 By Nasdaq GlobeNewswire